Yanhua Zheng

Suggest Changes
Learn More
During the past decades, agents with novel mechanisms of action, such as monoclonal antibodies (MAbs) and histone deacetylase inhibitors (HDACis) have been applied to treat relapsed or refractory(More)
  • 1